● PRNewsWireNov 17, 2026 · 09:18 ETCOMPANY'S OWN WORDS
RedHill Biopharma (Nasdaq: RDHL) Highlights Strategic Transformation and Expanded Commercial Growth Strategy in Virtual Investor "What This Means" Segment
Chief Business Officer, Guy Goldberg, discusses the Company's evolution into a more scalable commercial-stage business, opportunities to drive growth across its expanded GI portfolio and its long-term vision for sharehol…
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate
In vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP) and its MAP-killing comparability to RedHill's RHB-104 in bo…
Comparing Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Redhill Biopharma (NASDAQ:RDHL)
Redhill Biopharma (NASDAQ: RDHL - Get Free Report) and Zentalis Pharmaceuticals (NASDAQ: ZNTL - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two busines…
● PRNewsWireSep 30, 2026 · 16:05 ETCOMPANY'S OWN WORDS
RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5 million in 2025 net sales…
Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)
Novartis (NYSE: NVS - Get Free Report) and Redhill Biopharma (NASDAQ: RDHL - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of thei…
● PRNewsWireSep 1, 2026 · 07:00 ETCOMPANY'S OWN WORDS
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that togeth…
● PRNewsWireAug 31, 2026 · 07:00 ETCOMPANY'S OWN WORDS
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational pr…
Article counts from the last market-wide feed page, across every symbol we track and not just RDHL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.